Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Daily Top 10 COVID-19 publications

Deutsch | English | Español | Français | Italiano | Português; | Tiếng Việt | Türkçe


  Free Subscription


1 Am J Psychiatry
1 Biol Psychiatry
3 Mol Psychiatry
2 Neuropsychopharmacology
1 PLoS One
4 Psychiatry Res
2 Psychol Med
7 Schizophr Res

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Psychiatry

    Psychotic Experiences, Cognitive Decline, and Genetic Vulnerabilities in Relation to Developing Psychotic Disorders.
    Am J Psychiatry. 2020;177:279-281.

    Biol Psychiatry

  2. WATTS JJ, Jacobson MR, Lalang N, Boileau I, et al
    Imaging Brain Fatty Acid Amide Hydrolase in Untreated Patients With Psychosis.
    Biol Psychiatry. 2020 Mar 12. pii: S0006-3223(20)31299.
    PubMed         Abstract available

    Mol Psychiatry

  3. PRICE AJ, Jaffe AE, Weinberger DR
    Cortical cellular diversity and development in schizophrenia.
    Mol Psychiatry. 2020 May 13. pii: 10.1038/s41380-020-0775.
    PubMed         Abstract available

  4. WILLIAMS SE, Mealer RG, Scolnick EM, Smoller JW, et al
    Aberrant glycosylation in schizophrenia: a review of 25 years of post-mortem brain studies.
    Mol Psychiatry. 2020 May 13. pii: 10.1038/s41380-020-0761.
    PubMed         Abstract available

  5. KRAGULJAC NV, Anthony T, Morgan CJ, Jindal RD, et al
    White matter integrity, duration of untreated psychosis, and antipsychotic treatment response in medication-naive first-episode psychosis patients.
    Mol Psychiatry. 2020 May 12. pii: 10.1038/s41380-020-0765.
    PubMed         Abstract available


  6. KANTROWITZ JT, Grinband J, Goff DC, Lahti AC, et al
    Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers.
    Neuropsychopharmacology. 2020 May 13. pii: 10.1038/s41386-020-0706.
    PubMed         Abstract available

  7. BUSTILLO JR, Upston J, Mayer G, Jones T, et al
    Glutamatergic hypo-function in the left superior and middle temporal gyri in early schizophrenia: a data-driven three-dimensional proton spectroscopic imaging study.
    Neuropsychopharmacology. 2020 May 13. pii: 10.1038/s41386-020-0707.
    PubMed         Abstract available

    PLoS One

  8. LEE J, Green MF, Nuechterlein KH, Swerdlow NR, et al
    The effects of age and sex on cognitive impairment in schizophrenia: Findings from the Consortium on the Genetics of Schizophrenia (COGS) study.
    PLoS One. 2020;15:e0232855.
    PubMed         Abstract available

    Psychiatry Res

  9. HUARCAYA-VICTORIA J, Herrera D, Castillo C
    Psychosis in a patient with anxiety related to COVID-19: A case report.
    Psychiatry Res. 2020;289:113052.

  10. MASAOKA Y, Velakoulis D, Brewer WJ, Cropley VL, et al
    Impaired olfactory ability associated with larger left hippocampus and rectus volumes at earliest stages of schizophrenia: A sign of neuroinflammation?
    Psychiatry Res. 2020;289:112909.
    PubMed         Abstract available

  11. MARTIN DR, Gonzalez AJ, Perez CPL, Sesmero SA, et al
    New-onset psychosis in COVID-19 pandemic: a case series in Madrid.
    Psychiatry Res. 2020 May 13:113097. doi: 10.1016/j.psychres.2020.113097.

  12. KILIAN S, Asmal L, Phahladira L, Plessis SD, et al
    The association between childhood trauma and treatment outcomes in schizophrenia spectrum disorders.
    Psychiatry Res. 2020;289:113004.
    PubMed         Abstract available

    Psychol Med

  13. COX ER, Marwick KFM, Hunter RW, Priller J, et al
    Dialysis and plasmapheresis for schizophrenia: a systematic review.
    Psychol Med. 2020 May 14:1-8. doi: 10.1017/S0033291720001324.
    PubMed         Abstract available

  14. HUBL D, Michel C, Schultze-Lutter F, Hauf M, et al
    Basic symptoms and gray matter volumes of patients at clinical high risk for psychosis.
    Psychol Med. 2020 May 14:1-9. doi: 10.1017/S0033291720001282.
    PubMed         Abstract available

    Schizophr Res

  15. MONTAGNESE M, Knolle F, Haarsma J, Griffin JD, et al
    Reinforcement learning as an intermediate phenotype in psychosis? Deficits sensitive to illness stage but not associated with polygenic risk of schizophrenia in the general population.
    Schizophr Res. 2020 May 7. pii: S0920-9964(20)30229.
    PubMed         Abstract available

  16. BROWN E, Gray R, Lo Monaco S, O'Donoghue B, et al
    The potential impact of COVID-19 on psychosis: A rapid review of contemporary epidemic and pandemic research.
    Schizophr Res. 2020 May 6. pii: S0920-9964(20)30257.
    PubMed         Abstract available

  17. PILLNY M, Schlier B, Lincoln TM
    "I just don't look forward to anything". How anticipatory pleasure and negative beliefs contribute to goal-directed activity in patients with negative symptoms of psychosis.
    Schizophr Res. 2020 May 7. pii: S0920-9964(20)30170.
    PubMed         Abstract available

  18. KUMARI V, Ettinger U
    Controlled sleep deprivation as an experimental medicine model of schizophrenia: An update.
    Schizophr Res. 2020 May 8. pii: S0920-9964(20)30175.
    PubMed         Abstract available

  19. WOODS SW, Bearden CE, Sabb FW, Stone WS, et al
    Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit.
    Schizophr Res. 2020 May 10. pii: S0920-9964(20)30227.
    PubMed         Abstract available

  20. WANG SP, Wang JD, Chang JH, Wu BJ, et al
    Frailty affects employment outcomes in patients with schizophrenia in noncompetitive employment: A 4-year longitudinal study.
    Schizophr Res. 2020 May 10. pii: S0920-9964(20)30233.
    PubMed         Abstract available

  21. FORMICA MJC, Phillips LJ, Hartmann JA, Yung AR, et al
    Has improved treatment contributed to the declining rate of transition to psychosis in ultra-high-risk cohorts?
    Schizophr Res. 2020 May 10. pii: S0920-9964(20)30235.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.